Literature DB >> 26544127

AbbVie buys last available priority voucher for $350 million.

Chris Morrison.   

Abstract

Mesh:

Year:  2015        PMID: 26544127     DOI: 10.1038/nbt1115-1120

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  New class PCSK9 blockers stride into cholesterol market.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2015-08       Impact factor: 54.908

2.  FDA launches priority vouchers for neglected-disease drugs.

Authors:  Emily Waltz
Journal:  Nat Biotechnol       Date:  2008-12       Impact factor: 54.908

3.  The price of priority review: $67.5 million.

Authors:  Melanie Senior
Journal:  Nat Biotechnol       Date:  2014-10       Impact factor: 54.908

  3 in total
  2 in total

1.  Managing intellectual property to develop medicines for the world's poorest.

Authors:  Sylvie Fonteilles-Drabek; David Reddy; Timothy N C Wells
Journal:  Nat Rev Drug Discov       Date:  2017-02-24       Impact factor: 84.694

2.  Spanish group defeats Shkreli in Chagas voucher race.

Authors:  Lisa Melton
Journal:  Nat Biotechnol       Date:  2017-11-09       Impact factor: 54.908

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.